tbuckley/cabot-search huggingface dataset:
Abstract 2596: Suppression of lung cancer malignancy by peptides targeting MARCKS phosphorylation site domain: A comparative study
Authors: Ching-Hsien Chen, Sarah Statt, Phillip Thai, Jasmine G. Lee, Kenneth B. Adler, Pan-Chyr Yang, Reen Wu
Journal: Cancer Research (2014)

Abstract We have recently reported elevated MARCKS phosphorylation (p-MARCKS) in lung cancer tissues but not in their adjacent normal non-cancer tissue sections. We have extended this study to a tumor tissue array from a cohort of 110 human patients with lung cancer. Immunohistochemistry results have shown a significant association of elevated p-MARCKS with advanced-stage, lymph node metastasis and malignant phenotypes of lung cancer, confirming the importance of p-MARCKS in lung cancer progression. To see if this newly discover biomarker can be a target for therapeutic treatment for the suppression of lung cancer malignancy, we have employed two peptides for this potential; one is the MANS peptide developed by our collaborator many years ago to target myristoylated N-terminal amino acid region for the control of airway mucus granule secretion, the other peptide is MPS that directly targets the MARCKS phosphorylation site domain. For MANS peptide, our recent publication has shown it is effective in blocking lung cancer cell migration and invasiveness in vitro as well as in vivo metastasis. A similar observation was seen for MPS peptide treatment. However, in contrast to MANS peptide, MPS treatment can directly block PIP3-dependent AKT signaling and repress lung tumor growth in vivo in addition to the suppression of metastasis, while MANS can only reduce cancer metastasis. These results support the initial notion on the involvement of p-MARCKS as a biomarker in lung cancer and the potential to target the phosphorylation site domain for controlling cancer progression. Our data have also suggested a direct targeting MARCKS phosphorylation site domain by MPS peptide is more effective in the suppression of lung cancer malignancy. Citation Format: Ching-Hsien Chen, Sarah Statt, Phillip Thai, Jasmine G. Lee, Kenneth B. Adler, Pan-Chyr Yang, Reen Wu. Suppression of lung cancer malignancy by peptides targeting MARCKS phosphorylation site domain: A comparative study. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2596. doi:10.1158/1538-7445.AM2014-2596
Kinetics of nasopharyngeal shedding of novel H1N1 (swine-like) influenza A virus in an immunocompetent adult under oseltamivir therapy
Authors: C. Charlier, V. Enouf, F. Lanternier, M. Grandadam, K. Amazzough, S. Blanche, M. Lecuit, O. Lortholary, S. van der Werf
Journal: Clinical Microbiology and Infection (2009)
Assessing the effect of foreign travel and protection by BCG vaccination on the spread of tuberculosis in a low incidence country, United Kingdom, October 2008 to December 2009
Authors: I Abubakar, T Matthews, D Harmer, E Okereke, K Crawford, T Hall, T Collyns, G Smith, A Barrett, S Baugh
Journal: Eurosurveillance (2011)

Binary file ES_Abstracts_Final_ECDC.txt matches
Clusterin contributes to caspase-3–independent brain injury following neonatal hypoxia-ischemia
Authors: Byung Hee Han, Ronald B. DeMattos, Laura L. Dugan, Jeong Sook Kim-Han, Robert P. Brendza, John D. Fryer, Malca Kierson, John Cirrito, Kevin Quick, Judith A. K. Harmony, Bruce J. Aronow, David M. Holtzman
Journal: Nature Medicine (2001)
Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma
Authors: Berno Dankbar, Teresa Padró, Regine Leo, Birgit Feldmann, Martin Kropff, Rolf M. Mesters, Hubert Serve, Wolfgang E. Berdel, Joachim Kienast
Journal: Blood (2000)
Suicide rate rises after funeral of Princess of Wales
Authors: Raj Persaud
Journal: BMJ (2000)

A rise in the suicide rate in England and Wales followed the funeral of Princess Diana three years ago, a new study shows. The University of Oxford Centre for Suicide Research found that the overall suicide rate in England and Wales rose by 17% in the four weeks after her funeral, compared with the average reported for that period in the four previous years ( British Journal of Psychiatry 2000;177:469-72).

The number of people taking their life in this period increased by 40, but the …
THE COMPLICATIONS AND HAZARDS OF FEVER THERAPY: ANALYSIS OF 1000 CONSECUTIVE FEVER TREATMENTS WITH THE KETTERING HYPERTHERM
Authors: Robert M. Stecher, Walter M. Solomon
Journal: Annals of Internal Medicine (1937)

Article1 January 1937THE COMPLICATIONS AND HAZARDS OF FEVER THERAPY: ANALYSIS OF 1000 CONSECUTIVE FEVER TREATMENTS WITH THE KETTERING HYPERTHERMROBERT M. STECHER, M.D., WALTER M. SOLOMON, M.D.ROBERT M. STECHER, M.D.Search for more papers by this author, WALTER M. SOLOMON, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-10-7-1014 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe beneficial effect of intercurrent infection upon patients with chronic disease was noted many years ago and naturally suggested the therapeutic value of elevated body temperatures. The feasibility of such a form of nonspecific treatment was tested with tuberculin shortly after its introduction about 50 years ago. This was the first of a long series of suggestions for therapeutic fever production which have included the utilization of febrile diseases, protein fevers and numerous mechanical and electrical devices. Despite the large number of methods which have been recommended and are available, the end is not yet in sight, and scarcely a... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Cleveland, Ohio*Received for publication October 30, 1936.From the Department of Medicine, Western Reserve University Medical School at City Hospital, Cleveland, Ohio. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byPersistence of EEG Activity with Prolonged Induced Hyperthermic FeverTreatment of Gonorrheal Arthritis: An Analysis of 200 CasesRecent Researches on Arthritis and Rheumatism in the United States 1 January 1937Volume 10, Issue 7Page: 1014-1020KeywordsFeversHospital medicineHyperthermiaInfectious diseasesProteinsTemperatureTuberculin ePublished: 1 December 2008 Issue Published: 1 January 1937 PDF downloadLoading ...
Abstract 1733: Complete Ablation of Typical Atrial Flutter in Patients with Corrected Congenital Heart Defects: “Non-Traditional” Access to the Surgically Excluded Cavotricuspid Isthmus
Authors: Malek M El Yaman, Samuel J Asirvatham, Douglas L Packer, Co-burn J Porter
Journal: Circulation (2007)

Background: Although multiple macroreentrant atrial flutters are seen in postoperative patients with congenital heart disease, cavotricuspid isthmus (CVTI) dependent flutter remains a fairly common arrhythmia in this group. When a Fontan or atrial switch (Mustard/Senning) type of procedure is performed, a portion of the CVTI is excluded from catheter access obtainable via a systemic venous route. We evaluated different techniques to access this excluded portion and completely ablate CVTI dependent flutter. Methods/Results: Between 1990 and 2007, 140 patients with surgically corrected congenital heart disease underwent an ablation procedure at our institution. Their records were reviewed to identify those with prior Fontan or atrial switch procedure who had documented CVTI dependent flutter requiring ablation. Data collected included methods of catheter access, circuits observed or induced, the location and number of ablation lines, immediate and long-term success, and complications. Results: Sixteen patients were identified (14, Fontan; 2, Mustard). In 12/16 (75%) patients bidirectional block of CVTI dependent flutter could not be achieved by right atrial (venous approach) ablation alone. In 7 of those, the excluded portion of the CVTI was targeted for ablation. This was accomplished by a retrograde transaortic approach via an interventricular communication then through the right atrioventricular valve (5 patients). Another retrograde transaortic approach was used with the catheter crossing the left atrioventricular valve then an atrial septal communication (one patient). A third approach involved an antegrade transconduit puncture (one patient). In all 7 patients, successful ablation of CVTI dependent flutter with bidirectional block was achieved. Post-procedure, one patient had temporary AV block requiring pacemaker placement. Follow-up was available on 4/7 patients (3 to 22 months, mean 10 months) with no documented recurrence of their CVTI dependent flutter. Conclusion: Even when surgical procedures exclude a portion of the CVTI, complete ablation for typical atrial flutter with resulting bidirectional block can be achieved via “non-traditional” approaches targeting the surgically excluded arrhythmogenic tissue.
Expression of transforming growth factor β1 by human endometrial carcinoma cell lines : inverse correlation with effects on growth rate and morphology
Authors: Jeff A. Boyd, David G. Kaufman
Journal: Cancer Research (1990)

Abstract  We examined the effects of transforming growth factor β 1  (TGF-β 1 ) on various aspects of the cell biology of human endometrial carcinoma (HEC) cell lines  in vitro , as well as the expression of TGF-β 1  mRNA by these cell lines. Cell lines from eight HEC tumors, representing a variety of histological subtypes, were studied in order to test the generality of conclusions regarding the effects of TGF-β 1  on this particular tumor cell type. The growth of five HEC cell lines was inhibited by TGF-β 1  (10 ng/ml), while growth of three cell lines was not inhibited. The effects on growth correlated with morphological alterations induced by TGF-β 1 ; the cell lines with inhibited growth displayed a larger, flatter, more contact-inhibited phenotype, while the cell lines whose growth was not inhibited showed few discernible morphological alterations in response to TGF-β 1 . Northern analysis of TGF-β 1  mRNA levels revealed that the three HEC cell lines unresponsive to TGF-β 1  treatment expressed relatively large amounts of TGF-β 1 . Correspondingly, the five HEC cell lines which responded to TGF-β 1  with growth and morphological changes expressed much lower levels of TGF-β 1  mRNA. These results suggest that the sensitivity of human HEC cell lines to TGF-β 1  is variable and that this sensitivity is inversely correlated with the level of expression of TGF-β 1 .
Hair Dye Use and Non-Hodgkin Lymphoma
Authors: Shelia Hoar Zahm, Joseph F Fraumeni
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
AMEBIASIS IN MILITARY OVERSEAS RETURNEES
Authors: Donald F. Marion, Frederick N. Sweetsir
Journal: Annals of Internal Medicine (1946)

Article1 February 1946AMEBIASIS IN MILITARY OVERSEAS RETURNEESDONALD F. MARION, FREDERICK N. SWEETSIRDONALD F. MARIONSearch for more papers by this author, FREDERICK N. SWEETSIRSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-24-2-186 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptINTRODUCTIONThere is no accurate estimate of the incidence of amebiasis in the United States. The results of independent and uncoördinated local surveys have failed to predict an acceptable national figure because of the failure in most instances to utilize accepted criteria for uniform and dependable studies. Despite the incredibly divergent estimates which have been published in recent years, general agreement has tentatively placed the incidence of carriers somewhere between Craig's 10 per cent1and Faust's 20 per cent2of the total population. Recently Brown, McHardy, and Spellberg3have reported 14.1 per cent incidence in a Louisiana survey of ambulatory...Bibliography1. CRAIGFAUST CFEC: Clinical parasitology, 2nd Ed., 1940, Lea and Febiger Co., Philadelphia. CrossrefGoogle Scholar2. FAUST EC: Prevalence of amebiasis in Western Hemisphere, Am. Jr. Trop. Med., 1942, xxii, 93-111. CrossrefGoogle Scholar3. BROWNMCHARDYSPELLBERG ECGMA: Statistical evaluation of amebiasis, Gastroenterology, 1945, iv, 154-163. Google Scholar4. SAPEROJOHNSON JJCM: Incidence of amebiasis in U. S. Naval recruits, U. S. Nav. Med. Bull., 1939, xxxvii, 279-285. Google Scholar5. FLORIO L: Introduction of exotic diseases into the United States, Rocky Mt. Med. Jr., 1944, xxxxi, 643-647. Google Scholar6. FAUST EC: Amebiasis in the New Orleans population as revealed by autopsy examination of accident cases, Am. Jr. Trop. Med., 1941, xxi, 35-48. CrossrefGoogle Scholar7. HORSTER A: Amebic dysentery in North Africa and its prevention, Deutsch. tropenmed. Ztschr., 1943, xxxxvii, 299-302. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: DONALD F. MARION; FREDERICK N. SWEETSIR*Received for publication June 28, 1945.From the AAF Regional Hospital, Coral Gables, Fla. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byDiagnosis of Amebiasis by Stool ExaminationPostwar Tropical Diseases in the United States 1 February 1946Volume 24, Issue 2 Page: 186-191 Keywords Amebiasis Armed forces ePublished: 1 December 2008 Issue Published: 1 February 1946 PDF downloadLoading ...
Hyperoxic reperfusion is required to reduce infarct size after intravenous therapy with perfluorochemical (Fluosol-DA 20%) or its detergent component (poloxamer 188) in a poorly collateralized animal model
Authors: Frank D. Kolodgie, Andrew Farb, Greg C. Carlson, Patricia S. Wilson, Renu Virmani
Journal: Journal of the American College of Cardiology (1994)
Electrical Therapy for Cardiac Arrhythmias: Pacing, Antitachycardia Devices, Catheter Ablation
Authors: Sanjeev Saksena, Nora Goldschlager
Journal: Annals of Internal Medicine (1990)

A comprehensive presentation of electrical therapy by more than 40 highly respected authorities, including complete coverage of tachycardia (fast rate) therapy, as well as bradycardias (conventional cardiac pacing). This valuable text also details concepts of arrhythmia prevention or ablation with electrical techniques...device implantation techniques* electrocardiographic, radiologic, and device monitoring techniques, much more.
Abstract 3046: Protective Effect Of Preoperative Angiotensin Converting Enzyme Inhibitors On Renal Outcome Following Coronary Artery Bypass Graft Surgery. A Propensity Score-adjusted Analysis
Authors: Umberto Benedetto, Simone Refice, Antonino Roscitano, Fabio Capuano, Caterina Simon, Cosimo Comito, Gian Domenico Di Nucci, Emiliano Angeloni, Riccardo Sinatra
Journal: Circulation (2007)

Introduction: A large number of patients undergoing coronary artery bypass graft (CABG) surgery are treated with angiotensin converting enzyme (ACE) inhibitors before the operation. Since ACE inhibitors decrease glomerular perfusion pressure, it is still believed that their withdrawal before surgery on cardiopulmonary bypass may reduce postoperative renal adverse events. However, no previous study has attempted to address this issue. We aimed to evaluate the impact of preoperative ACE inhibitors on renal outcome in patients undergoing on pump CABG surgery using a risk adjusted approach. Methods and Results: A propensity score-based analysis of 531 patients undergoing elective isolated CABG surgery on cardiopulmonary bypass. Patients with preoperative end-stage renal failure requiring dialysis were excluded. Of those 531 patients, 204 were treated with ACE inhibitors before the operation and 327 were not treated with ACE inhibitors. Renal adverse outcome following surgery was defined as 20% decrease in creatinine clearance from preoperative or post-operative mechanical renal support. After adjusting for propensity score and covariates, multivariate analysis showed that preoperative ACE inhibitors had a protective effect against renal adverse outcome following CABG surgery (odds ratio [OR], 0.8; 95% confidence interval [CI],0.5 to 0.9; P &lt;0.01). Other independent predictors of adverse renal outcome were age (OR 1.17 per 1 years; 95% CI 1.01 to 1.39; P &lt;0.001), female sex (OR 0.72; 95% CI 0.51 to 0.93; P &lt;0.001); left ventricular ejection fraction less than 0.30 (OR 2.12; 95% CI 1.92 to 2.85; P &lt;0.01); pre-operative creatinine clearance (OR 1.23 per 10ml/min decrease; 95% CI 1.01 to 1.31; P &lt;0.001); diabetes (OR 1.80; 95% CI 1.25 to 2.24; P &lt;0.01); aortic cross clamp time (OR 1.31 per 10 min increase; 95% CI 1.11 to 1.61; P &lt;0.01). Operative mortality was not statistically different between groups (2.4% versus 4.0% in patients with and without preoperative ACE inhibitors; P =0.45) Conclusions: Preoperative ACE inhibitors are associated with better renal outcome in patients undergoing on pump CABG surgery. No clinical evidences support ACE inhibitors withdrawal before surgery
Do chronic myeloid leukemia patients with late “warning” responses benefit from “watch and wait” or switching therapy to a second generation tyrosine kinase inhibitor?
Authors: Valentin García‐Gutiérrez, Jose Manuel Puerta, Begoña Maestro, Luis Felipe Casado Montero, Alfonso Muriel, Jose Ramon Molina Hurtado, Manuel Perez‐Encinas, Maria Victoria Moreno Romero, Pere Barba Suñol, Ricardo Sola Garcia, Raquel De Paz, Maria Jose Ramirez Sanchez, Santiago Osorio, Maria Isabel Mata Vazquez, Joaquin Martinez López, Jose Luis Sastre, Maria de los Angles Portero, Guiomar Bautista, Maria Soledad Duran Nieto, Pilar Giraldo, Margarita Jimenez Jambrina, Carmen Burgaleta, Joaquin Ruiz Aredondo, Maria Jesús Peñarrubia, Maria José Requena, María del Carmen Fernández Valle, Carmen Calle, Antonio Paz Coll, Jose Ángel Hernández‐Rivas, Rafael Franco Osorio, Pilar Cano, David Tallón Pérez, Margarita Fernández de la Mata, Pilar López Garrido, Juan Luis Steegmann
Journal: American Journal of Hematology (2014)

In the latest recommendations for the management of chronic-phase chronic myeloid leukemia suboptimal responses have been reclassified as "warning responses." In contrast to previous recommendations current guidance advises close monitoring without changing therapy. We have identified 198 patients treated with first-line imatinib, with a warning response after 12 months of treatment (patients with a complete cytogenetic response but no major molecular response [MMR]). One hundred and forty-six patients remained on imatinib, while 52 patients changed treatment to a second generation tyrosine kinase inhibitor (2GTKI). Changing therapy did not correlate with an increase in overall survival or progression-free survival. Nevertheless, a significant improvement was observed in the probability of a MMR: 24% vs. 42% by 12 months and 43% vs. 64% by 24 months (P = 0.002); as well as the probability of achieving a deep molecular responses (MR(4.5) ): 1% vs. 17% and 7% vs. 23% by 12 and 24 months, respectively (P = <0.001) .The treatment change to 2GTKI remained safe; however, we have observed a 19% of treatment discontinuation due to side effects. We have observed an improvement of molecular responses after changing treatment to 2GTKI in patients with late suboptimal response treated with imatinib first line. However, these benefits were not correlated with an improvement of progression free survival or overall survival.
Isoflavones and Postmenopausal Women
Authors: Cesare R Sirtori
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Journals' Freedom to Publish Affirmed
Authors: Mike Mitka
Journal: JAMA (2004)

EDITORS OF PEER-REVIEWED SCIENtific journals are breathing sighs of relief following an April 2 ruling that should keep the US government out of the editing process. Until last September, most scientific journals believed that federal embargo restrictions from sanctioned countries did not apply to scientific publishing. But a decision last September, following a rule-clarification request by the Institute of Electrical and Electronic Engineers (IEEE), threw the matter up in the air. In that ruling, the US Department of the Treasury’s Office of Foreign Assets Control (OFAC) said journals could publish manuscripts from authors living in countries facing US trade embargoes—Cuba, Iran, Libya, and Sudan— but could not edit such papers. The government argued that the editorial process, including peer review, was considered a “service” which added economic value to a manuscript and was thus prohibited under the International Emergency Economic Power’s Act and the Trading with the Enemy Act.